Current therapies for treating castration resistant prostate cancer (CRPC) include
abiraterone and enzalutamide which function by inhibiting androgen signaling by targeting …

Background: Androgen receptor signaling remains important in castration-resistant prostate
cancer (CRPC) as demonstrated by the efficacy of abiraterone acetate (henceforth …

Introduction: Over the past decade, treatment options for men with metastatic castration-
resistant prostate cancer (CRPC) have expanded with the addition of abiraterone acetate …

Despite the recent approval and widespread use of abiraterone acetate and enzalutamide
for the treatment of castration-resistant prostate cancer (CRPC), this disease still poses …

Prostate cancer (PCa) is the 2nd leading cause of cancer-related death among men in the
United States and its progression is tightly associated with the androgen/androgen receptor …

Introduction Prostate cancer is the most common malignancy in the male. Androgen-
deprivation therapy (ADT) has been the mainstay in the treatment of metastatic prostate …

Recent data report that abiraterone acetate, a specific inhibitor of CYP17 that is key to
androgen and estrogen synthesis, improves survival in metastatic castration-resistant …

Androgen receptor blockade is a cornerstone of treatment for prostate cancer. Despite
castrate levels of testosterone, activation of the androgen receptor remains an important …

The survival benefit conferred by two hormonal agents in phase III trials has clinically
validated the long suspected and now widely recognized phenomenon of castration …

Evaluation of: Reid AH, Attard G, Danila DC et al. Significant and sustained antitumor activity
in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone …